Your browser does not support iframes.
Teva is working to bring relief to people suffering from migraines – and in particular the destruction of quality of life that chronic or high frequency episodic migraine brings. TEV-48125 is a monoclonal antibody that binds to calcitonin gene-related peptide (CGRP). CGRP causes headaches in migraine patients, and we know that CGRP levels are elevated during migraine. As such, targeting CGRP has the potential to change the way migraine is treated. TEV-48125 is currently in Phase IIb clinical trials for prevention of chronic and episodic migraine. TEV-48125 demonstrates our determination to develop much needed treatment options for people suffering from migraine. We continue to pursue effective solutions in the prevention and treatment of migraine in order to make a real and meaningful difference to patients’ lives.